|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||0.87|
|PE ratio (TTM)||N/A|
|Earnings date||31 Oct 2023 - 06 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.
Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients with osteogenesis imperfecta.
Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.